ycoguqi.wordpress.com
The trial, called ADVANCE, will determine the efficacy and safetyhof Biogen’s drug target, called PEGylated interferon beta-1a, in reducin g relapse rates in patients with multiple sclerosie (RMS). The global study will enroll morethan 1,200o patients with RMS between the ages of 18 and 55. The study’ss goal is to determine whethed the drug reduces the annualized relapse rate in patientws with RMS atone year. The studyu will also examine if, over time, the potential treatment can slow diseass progression and lead to a decrease in the numbeer of a certain kind of brain lesionsw commonly seen inMS patients.
The treatment is a combinatiohn ofInterferon beta-1a, whichh has been used successfully to treat MS for more than 10 and PEGylation, which can extend the amounf of time a drug remains in a patient’s system. If the trial is the treatment has the potential to reduce the frequenchy of treatment injections and provide patients with an effective and more convenienrdosing option. Biogen’s (NASDAQ: BIIB) stock was trading at in $49.3 3 in morning trading on Monday, down from the previouz close of $51.67.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment